NCT05961384View on ClinicalTrials.gov

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

January 15, 2022

Study Completion Date

January 15, 2022

Conditions

Hypertension

Interventions

DRUG

baxdrostat

a blood pressure lowering drug, oral dose

Trial Locations (1)

53704

Labcorp Clinical Research Unit, Madison

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY